Bremelanotide comment watch save

  • FDA APPROVAL DATE: 06/21/2019
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Naltrexone
  • PREGNANCY: Advise patients to discontinue treatment if pregnancy is suspected.

Please login to view the rest of this drug profile.

Page last updated 05/07/2025

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top